---
title: '2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy-
  and chemoradiotherapy-induced nausea and vomiting'
date: '2023-12-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38097904/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231215170616&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: As for the previous guideline, the serotonin receptor antagonists
  are still the cornerstone in antiemetic prophylaxis of nausea and vomiting induced
  by high and moderate emetic risk radiotherapy. The guideline update provides new
  recommendation for the management of C-RINV for radiotherapy and concomitant weekly
  cisplatin. To avoid overtreatment, antiemetic prophylaxis is no longer recommended
  for the "low emetic risk" ...'
disable_comments: true
---
CONCLUSION: As for the previous guideline, the serotonin receptor antagonists are still the cornerstone in antiemetic prophylaxis of nausea and vomiting induced by high and moderate emetic risk radiotherapy. The guideline update provides new recommendation for the management of C-RINV for radiotherapy and concomitant weekly cisplatin. To avoid overtreatment, antiemetic prophylaxis is no longer recommended for the "low emetic risk" ...